2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.114 Zaid Al-Saheli NACLC23 Abstract

PP01.114 Zaid Al-Saheli NACLC23 Abstract

Pdf Summary

A retrospective study was conducted to evaluate the outcomes of patients diagnosed with lung cancer after being infected with COVID-19. The study included 86 patients who were diagnosed with either small cell or non-small cell lung cancer within 6 months of their COVID-19 diagnosis. The primary endpoint was overall survival (time from lung cancer diagnosis to death), and the secondary endpoint was progression-free survival (time from lung cancer diagnosis to progression or death).<br /><br />The analysis found that the majority of patients (66.3%) were diagnosed with non-squamous NSCLC, followed by squamous NSCLC (17.4%) and SCLC (16.3%). The average age of the patients was 70 years, with a higher percentage of females (62%) than males (38%). The majority of patients were Caucasians (65%), and 23% were African Americans. The average Charlson Comorbidity Index score was 3.1, indicating the presence of other health conditions. Additionally, 70.6% of patients were diagnosed with Chronic Obstructive Pulmonary Disease (COPD).<br /><br />The study found that the percentage of patients diagnosed with early-stage NSCLC was higher compared to the pre-COVID incidence rate. The treatments received by the patients included surgery, radiation, chemotherapy, immunotherapy, and targeted therapy. The outcomes of the patients who received standard of care treatments were consistent with their anticipated stage-adjusted survival.<br /><br />In conclusion, this retrospective analysis suggests that the incidence of early-stage NSCLC was higher among patients diagnosed with lung cancer after COVID-19 infection. Despite the presence of comorbidities and COVID-19 infection, patients were able to receive appropriate treatments and their outcomes were in line with expectations for their stage of lung cancer.

Keywords

retrospective study

lung cancer

COVID-19

patients

NSCLC

SCLC

treatments

incidence rate

comorbidities

stage-adjusted survival